Yang Suk-Kyun
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Intest Res. 2025 Jul;23(3):233-253. doi: 10.5217/ir.2025.00073. Epub 2025 Jun 23.
Inflammatory bowel disease (IBD) was once considered rare in Korea, with the first reported case documented in 1961. Since then, its incidence and prevalence have increased markedly, accompanied by significant progress in clinical care and research. This narrative review traces the historical evolution of IBD in Korea, dividing the timeline into 4 periods: 1960-1979, 1980-1999, 2000-2019, and 2020-2039. For each period, major developments in the research environment and trends, diagnostic process, patient population and characteristics, and treatment are outlined. Over the past 6 decades, diagnostic and therapeutic approaches in Korea have advanced markedly, transitioning from limited diagnostic capacity and symptom-based management to practices that align with global standards. Notably, Korean patients with IBD exhibit distinctive clinical features compared with Western counterparts, including a markedly higher proportion of proctitis and a lower long-term risk of colectomy in ulcerative colitis, and a substantially higher prevalence of perianal fistulas in Crohn's disease, highlighting the need for population- specific strategies to advance personalized medicine. In parallel, the research landscape has evolved through multicenter collaborations, expanded research capacity, and growing international engagement, positioning Korea as an increasingly active contributor to the global IBD research community. Looking ahead, the future of IBD research in Korea is expected to be shaped by innovation-driven research, including advances in artificial intelligence, large-scale data integration, and deeper international collaboration. By tracing the clinical and research trajectory of IBD in Korea, this review offers insight into how the country has adapted to global trends and is preparing to meet future challenges.
炎症性肠病(IBD)在韩国曾被认为较为罕见,首例报告病例记录于1961年。自那时起,其发病率和患病率显著上升,同时临床护理和研究也取得了重大进展。这篇叙述性综述追溯了韩国IBD的历史演变,将时间线分为四个时期:1960 - 1979年、1980 - 1999年、2000 - 2019年以及2020 - 2039年。针对每个时期,概述了研究环境与趋势、诊断过程、患者群体及其特征以及治疗方面的主要进展。在过去的60年里,韩国的诊断和治疗方法有了显著进步,从有限的诊断能力和基于症状的管理转变为与全球标准接轨的实践。值得注意的是,与西方患者相比,韩国IBD患者表现出独特的临床特征,包括溃疡性结肠炎中直肠炎的比例明显更高以及结肠切除术的长期风险更低,克罗恩病中肛周瘘管的患病率大幅更高,这凸显了制定针对特定人群的策略以推进个性化医疗的必要性。与此同时,研究格局通过多中心合作、扩大研究能力以及增加国际参与度而不断演变,使韩国成为全球IBD研究界日益活跃的贡献者。展望未来,韩国IBD研究的未来预计将由创新驱动的研究塑造,包括人工智能的进展、大规模数据整合以及更深入的国际合作。通过追溯韩国IBD的临床和研究轨迹,本综述深入探讨了该国如何适应全球趋势并准备迎接未来挑战。